Ann: Prospectus, page-36

Just looking into imugenes cat 2 drugs for a min
most look like they are preclinical and partnered with pharma and
there market cap is sitting at 3 billion with 100mill in the bank
we are further advanced with our dmd program
and are.sitting at 100mill market cap
30x our market cap wow
are they that good
very frustrating to see as a lt shareholder, we should have a least partnered for the us route, held rights to they european market qnd the rest of the world would be enough for me
very dissapointed with the outcome, If our science is that good
y aren't pharma willing to collaborate in some form at this early stage
Could we get an answer for management as to why the cr raising route was taken?
seem like to me they just pump out these spark plus presentation with a few questions at the end, rehashing investor presentations
are they able to disclose to investors any offers if any that were on the table?